Effects of cholinesterase inhibitors on behavioural disturbances in alzheimer's disease: A systematic review

Drugs and Aging

Volumn 23, Issue 12, 2006, Pages 957-967

  Grimmer, Timo ^a   Kurz, Alexander ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DONEPEZIL; GALANTAMINE; PHOSPHATIDYLCHOLINE; PLACEBO; PSYCHOTROPIC AGENT; RIVASTIGMINE; TACRINE;

ALZHEIMER DISEASE; BEHAVIOR DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DEMENTIA; DISEASE ASSOCIATION; DRUG DOSE TITRATION; HUMAN; LIVER TOXICITY; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; RATING SCALE; REVIEW; RISK ASSESSMENT; SYMPTOMATOLOGY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ALZHEIMER DISEASE; BEHAVIORAL SYMPTOMS; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; HUMANS;

EID: 33845592950     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200623120-00003     Document Type: Review

References (44)

1. Devanand DP, Jacobs DM, Tang MX, et al. The course of psychopathologic features in mild to moderate Alzheimer disease. Arch Gen Psychiatry 1997; 54: 257-63
2. Holtzer R, Tang MX, Devanand DP, et al. Psychopathological features in Alzheimer's disease: course and relationship with cognitive status. J Am Geriatr Soc 2003; 51: 953-9
3. Hart DJ, Craig D, Compton SA, et al. A retrospective study of the behavioural and psychological symptoms of mid and late phase Alzheimer's disease. Int J Geriat Psychiatry 2003; 18: 1037-42
4. Coen RF, Swanwick GRJ, O'Boyle CA, et al. Behaviour disturbance and other predictors of carer burden in Alzheimer's disease. Int J Geriatr Psychiatry 1997; 12: 331-6
5. Hope T, Keene J, Gedling K, et al. Predictors of institutionalization for people with dementia living at home with a carer. Int J Geriat Psychiatry 1998; 13: 682-90
6. Steele C, Rovner B, Chase GA, et al. Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. Am J Psychiatry 1990; 147: 1049-51
7. Covinsky KE, Newcomer R, Fox P, et al. Patient and caregiver characteristics associated with depression in caregivers of patients with dementia. J Gen Intern Med 2003; 18: 1058-9
8. Giron MS, Forsell Y, Bernsten C, et al. Psychotropic drug use in elderly people with and without dementia. Int J Geriat Psychiatry 2001; 16: 900-6
9. Wilhelm-Goessling C. Antipsychotics given to elderly demented patients. Course in nursing homes after psychiatric hospital treatment. Nervenarzt 1998; 69: 999-1006
10. Lanctot KL, Best TS, Mittmann N, et al. Efficacy and safety of neuroleptics in behavioral disorders associated with dementia. J Clin Psychiatry 1998; 59: 550-61
11. Kindermann SS, Dolder CR, Bailey A, et al. Pharmacological treatment of psychosis and agitation in elderly patients with dementia: four decades of experience. Drugs Aging 2002; 19: 257-76
12. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005; 294: 1934-43
13. Ballard C, Waite J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. Cochrane Database Syst Rev 2006: CD003476
14. Snowden M, Sato K, Roy-Byrne P. Assessment and treatment of nursing home residents with depression or behavioral symptoms associated with dementia: a review of the literature. J Am Geriatr Soc 2003; 51: 1305-17
15. Courtney C, Farrell D, Gray R, et al. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 2004; 363: 2105-15
16. McKhann G, Folstein M, Katzman R, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-44
17. Gauthier S, Bouchard R, Lamontagne A, et al. Tetrafydroaminoacridine- lecithin combination treatment in patients with intermediatestage Alzheimer's disease. N Engl J Med 1990; 322: 1272-6
18. Davis KL, Thal LJ, Gamzu ER, et al. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. New Engl J Med 1992; 327: 1253-9
19. Farlow M, Gracon SI, Hershey LA, et al. A controlled trial of tacrine in Alzheimer's disease. JAMA 1992; 268: 2523-9
20. Forette F, Hoover T, Gracon S, et al. A double-blind, placebo-controlled, enriched population study of tacrine in patients with Alzheimer's disease. Eur J Neurol 1995; 2: 229-38
21. Knapp MJ, Knopman DS, Solomon PR, et al. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994; 271: 985-91
22. Wood PC, Castleden CM. A double-blind, placebo controlled, multicentre study of tacrine for Alzheimer's disease. Int J Geriatr Psychiatry 1994; 9: 649-54
23. Feldman H, Gauthier S, Hecker J, et al. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 2001; 57: 613-20
24. Holmes C, Wilkinson D, Dean C, et al. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology 2004; 63: 214-9
25. Tariot PN, Cummings JL, Katz IR, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheiemer's disease in the nursing home setting. J Am Geriatr Soc 2001; 49: 1590-9
26. Winblad B, Engedal K, Soininen H, et al. A 1-year, randomized, placebo-conrolled study of donepezil in patients with mild to moderate AD. Neurology 2001; 57: 489-95
27. Cummings JL, Schneider L, Tariot PN, et al. Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer's disease. Am J Psychiatry 2004; 161: 532-8
28. Rockwood K, Mintzer J, Truyen L, et al. Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial. J Neurol Neurosurg Psychiatry 2001; 71: 589-95
29. Seltzer B, Zolnouni P, Nunez M, et al. Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial. Arch Neurol 2004; 61: 1852-6
30. Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44: 2308-14
31. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984; 141: 1356-64
32. Starkstein SE, Mayberg HS, Preziosi TJ, et al. Reliability, validity, and clinical correlates of apathy in Parkinson's disease. J Neuropsychiatry Clin Neurosci 1992; 4: 134-9
33. Reisberg B, Borenstein J, Salob SP, et al. Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. J Clin Psychiatry 1987; 48: 9-15
34. Folstein MF, Folstein SE, McHugh PR. 'Mini Mental State'. A practical method for grading the cognitive state of patients for the clinician. J Psychiat Res 1975; 12: 189-98
35. Tariot PN, Solomon PR, Morris JC, et al. A 5-month, randomized, placebo-controlled trial of galantamine in Alzheimer's disease. Neurology 2000; 54: 2269-76
36. Dubois B, McKeith I, Orgogozo JM, et al. A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer's disease: the MALT study. Int J Geriatr Psychiatry 1999; 14: 973-82
37. Lopez-Arrieta JM, Schneider L. Metrifonate for Alzheimer's disease. Cochrane Database Syst Rev 2006: CD003155
38. Lanari A, Amenta F, Silvestrelli G, et al. Neurotransmitter deficits in behavioural and psychological symptoms of Alzheimer's disease. Mech Ageing Dev 2006; 127: 158-65
39. Trinh N, Hoblyn J, Mohanty S, et al. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease. A meta-analysis. JAMA 2003; 289: 210-6
40. Deberdt WG, Dysken MW, Rappaport SA, et al. Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia. Am J Geriatr Psychiatry 2005; 13: 722-30
41. Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia. A review of the evidence. JAMA 2005; 293: 596-608
42. De Deyn P, Jeste DV, Swanink R, et al. Aripiprazole for the treatment of psychosis in patients with Alzheimer's disease: a randomized, placebo-controlled study. J Clin Psychopharmacol 2005; 25: 463-7
43. De Deyn PP, Carrasco MM, Deberdt W, et al. Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease. Int J Geriatr Psychiatry 2004; 19: 115-26
44. Ballard C, Margallo-Lana M, Juszczak E, et al. Quetapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. BMJ 2005; 330 (7496): 874